Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/19/2024 | $32.00 | Equal-Weight | Morgan Stanley |
| 8/28/2024 | $35.00 | Overweight | Wells Fargo |
| 6/27/2024 | $29.00 | Sector Outperform | Scotiabank |
| 6/3/2024 | $20.00 | Underperform | Jefferies |
| 5/8/2024 | $25.00 → $35.00 | Market Perform → Outperform | Leerink Partners |
| 12/21/2023 | $23.00 | Neutral | Piper Sandler |
| 12/19/2023 | $20.00 | Equal Weight | Wells Fargo |
| 12/14/2023 | $23.00 | Buy | Guggenheim |
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies. Myriad's gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina's updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2). Previously, GIS to determine HRD was only available as a separate product. As a result, a broad array of cancer types will receive GIS results and their HRD status. "We are pleased to expand o
SALT LAKE CITY, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced that the Prequel® Prenatal Screen is now available at eight weeks into pregnancy. Enabled by its AMPLIFY™ technology, Prequel is the first and only prenatal cell-free DNA (cfDNA) screen available at eight-weeks gestational age. "Previously, I would schedule my patients to come in at eight weeks for their first prenatal appointment; then, I would ask them to come back two weeks later to do a Prequel screen. Now that Prequel can be performed at eight weeks, patients have the opportunity to complete all baseline lab work during that initial care
SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek, the #1 OBGYN-recommended gender test with over 99% accuracy,[1] is now available over the counter in more than 8,800 retail locations nationwide. The product is the first of its kind to be sold on shelf in Walmart stores greatly expanding access for expectant parents who want to learn if they're having a girl or boy at-home as early as six weeks into pregnancy. According to a 2024 consumer survey, 82% of expectant parents want to know the baby's sex before delivery, a
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experience in the life sciences sector. Her expertise spans intellectual property, litigation, and regulatory matters, gained through roles in both in-house and private practice settings at industry-leading companies. As Chief Legal Officer, Fox's responsibilities will encompass a wide range of areas, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquis
SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women's health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad. In her new role, she will support internal and external efforts to increase access to, and equity around, genetic testing throughout a woman's health journey including family planning, pregnancy management and hereditary cancer risk assessment. "We're thrilled to welcome Dallas
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial and clinical strategy to advance Myriad's oncology portfolio, which currently offers germline testing, tumor profiling and companion diagnostic options, including homologous recombinat
SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third quarter GAAP net loss improved to $22.1 million from a loss of $61.3 million in the third quarter of 2023 on improved revenue, gross margins and disciplined management of operating expenses. Third quarter adjusted EBITDA increased to $14.1 million from $1.4 million in third quarter of 2023.Third quarter GAAP loss per share improved to $(0.24) from $(0.75) in the third quarter of 2023; adjusted earnings (loss) per share improved to $0.06 from ($0.03) in the third quarter of 2023.Updated 2024 financial
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1st, 2025. After initial review of the updated policy, the company strongly disagrees with UnitedHealthcare's inclusion of GeneSight in its decision to change its coverage policy of multi-gene panels based on its rationale that there is insufficient evidence of efficacy to support coverag
SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the third quarter 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a
Morgan Stanley initiated coverage of Myriad Genetics with a rating of Equal-Weight and set a new price target of $32.00
Wells Fargo initiated coverage of Myriad Genetics with a rating of Overweight and set a new price target of $35.00
Scotiabank initiated coverage of Myriad Genetics with a rating of Sector Outperform and set a new price target of $29.00
10-Q - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
During the last three months, 4 analysts shared their evaluations of Myriad Genetics (NASDAQ:MYGN), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 1 1 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 1 0 2M Ago 0 1 1 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.0, a high estimate of $35.00, and a low estimate of $20.00. Observing a 15.08% increase, the current average ha
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)